相似文献
1
Anaplastic lymphoma kinase inhibitor development: enhanced delivery to the central nervous system.
Transl Lung Cancer Res. 2023 Aug 30;12(8):1822-1825. doi: 10.21037/tlcr-23-43. Epub 2023 Jul 31.
2
Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Jpn J Clin Oncol. 2021 Jan 1;51(1):37-44. doi: 10.1093/jjco/hyaa192.
3
Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
J Clin Pharmacol. 2022 Sep;62(9):1170-1176. doi: 10.1002/jcph.2056. Epub 2022 Apr 27.
4
Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Oncol Res Treat. 2019;42(11):599-606. doi: 10.1159/000502755. Epub 2019 Sep 17.
5
Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?
Cancer Radiother. 2019 Sep;23(5):432-438. doi: 10.1016/j.canrad.2019.03.009. Epub 2019 Jul 19.
6
Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.
Eur J Med Chem. 2019 Nov 15;182:111571. doi: 10.1016/j.ejmech.2019.111571. Epub 2019 Aug 9.
7
The characteristics of cerebrospinal fluid anaplastic large cells in a patient with primary leptomeningeal anaplastic large cell lymphoma.
Clin Chim Acta. 2022 Dec 1;537:46-50. doi: 10.1016/j.cca.2022.09.029. Epub 2022 Oct 13.
8
Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
Oncologist. 2020 Oct;25(10):867-877. doi: 10.1634/theoncologist.2020-0011. Epub 2020 Jul 23.
9
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
EBioMedicine. 2015 Dec 12;3:54-66. doi: 10.1016/j.ebiom.2015.12.009. eCollection 2016 Jan.
10
Success of Crizotinib Combined with Whole-Brain Radiotherapy for Brain Metastases in a Patient with Anaplastic Lymphoma Kinase Rearrangement-Positive Non-Small-Cell Lung Cancer.
Case Rep Oncol. 2018 Nov 29;11(3):777-783. doi: 10.1159/000492150. eCollection 2018 Sep-Dec.
引用本文的文献
1
Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase () rearrangements and co-existing alterations-a retrospective cohort study.
Transl Lung Cancer Res. 2023 Dec 26;12(12):2505-2519. doi: 10.21037/tlcr-23-658. Epub 2023 Nov 22.
本文引用的文献
1
ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis.
BMJ Open. 2022 Sep 19;12(9):e060782. doi: 10.1136/bmjopen-2022-060782.
2
Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
J Clin Pharmacol. 2022 Sep;62(9):1170-1176. doi: 10.1002/jcph.2056. Epub 2022 Apr 27.
3
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
Clin Cancer Res. 2022 Jun 13;28(12):2506-2516. doi: 10.1158/1078-0432.CCR-21-1838.
4
Isolated progression of miliary brain metastasis in a patient with stable lung adenocarcinoma successfully treated with whole-brain radiotherapy: A case report.
eNeurologicalSci. 2021 Aug 30;25:100366. doi: 10.1016/j.ensci.2021.100366. eCollection 2021 Dec.
5
Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an systems biology-based approach.
Oncotarget. 2021 Feb 16;12(4):316-332. doi: 10.18632/oncotarget.27875.
6
Advancing brain barriers RNA sequencing: guidelines from experimental design to publication.
Fluids Barriers CNS. 2020 Aug 18;17(1):51. doi: 10.1186/s12987-020-00207-2.
7
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23.
8
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Lancet. 2017 Mar 4;389(10072):917-929. doi: 10.1016/S0140-6736(17)30123-X. Epub 2017 Jan 24.
9
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Lancet Oncol. 2016 Apr;17(4):452-463. doi: 10.1016/S1470-2045(15)00614-2. Epub 2016 Mar 11.
10
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
EBioMedicine. 2015 Dec 12;3:54-66. doi: 10.1016/j.ebiom.2015.12.009. eCollection 2016 Jan.
Zotero 插件